Bicocca Open Archive

Logo unimib boa
CIACCIO, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.175
EU - Europa 3.376
AS - Asia 3.355
SA - Sud America 583
AF - Africa 122
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 12
Totale 14.638
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.735
SG - Singapore 1.231
IT - Italia 899
CN - Cina 759
DE - Germania 509
RU - Federazione Russa 455
BR - Brasile 425
CA - Canada 388
HK - Hong Kong 386
VN - Vietnam 380
SE - Svezia 362
IE - Irlanda 271
GB - Regno Unito 193
UA - Ucraina 190
IN - India 155
FR - Francia 130
BD - Bangladesh 82
FI - Finlandia 71
AT - Austria 61
DK - Danimarca 58
AR - Argentina 53
TR - Turchia 50
IQ - Iraq 41
ZA - Sudafrica 36
MX - Messico 35
ES - Italia 34
NL - Olanda 34
PL - Polonia 32
JP - Giappone 29
KR - Corea 28
EC - Ecuador 27
SA - Arabia Saudita 27
BE - Belgio 25
CO - Colombia 25
ID - Indonesia 23
VE - Venezuela 22
PH - Filippine 21
PK - Pakistan 21
DZ - Algeria 16
ET - Etiopia 16
MA - Marocco 14
UZ - Uzbekistan 14
MY - Malesia 13
JO - Giordania 12
TW - Taiwan 11
AU - Australia 10
EU - Europa 10
IR - Iran 10
AE - Emirati Arabi Uniti 8
CZ - Repubblica Ceca 8
KE - Kenya 8
OM - Oman 8
PY - Paraguay 8
AZ - Azerbaigian 7
CL - Cile 7
EG - Egitto 7
TN - Tunisia 7
IL - Israele 6
JM - Giamaica 6
NP - Nepal 6
PE - Perù 6
BG - Bulgaria 5
CH - Svizzera 5
UY - Uruguay 5
GA - Gabon 4
HU - Ungheria 4
LT - Lituania 4
MD - Moldavia 4
MM - Myanmar 4
RS - Serbia 4
TH - Thailandia 4
BH - Bahrain 3
BO - Bolivia 3
GR - Grecia 3
LB - Libano 3
MN - Mongolia 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PT - Portogallo 3
RO - Romania 3
TT - Trinidad e Tobago 3
CR - Costa Rica 2
DO - Repubblica Dominicana 2
HR - Croazia 2
KG - Kirghizistan 2
KW - Kuwait 2
LY - Libia 2
NC - Nuova Caledonia 2
SC - Seychelles 2
SN - Senegal 2
SR - Suriname 2
ZM - Zambia 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BB - Barbados 1
BF - Burkina Faso 1
BT - Bhutan 1
BW - Botswana 1
BY - Bielorussia 1
Totale 14.624
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.025
Singapore 753
Ashburn 614
San Jose 455
Woodbridge 448
Hong Kong 381
Fairfield 350
Houston 315
Chandler 311
Frankfurt am Main 292
Toronto 279
Dublin 262
Milan 242
Wilmington 219
New York 203
Jacksonville 178
Dearborn 154
Seattle 133
Los Angeles 130
Cambridge 127
Dallas 119
Beijing 117
Santa Clara 117
Princeton 104
Hanoi 93
Ho Chi Minh City 93
Chicago 87
The Dalles 87
Rome 73
Nanjing 66
Shanghai 61
Council Bluffs 58
Buffalo 54
Vienna 54
Altamura 53
Lauterbourg 48
Lawrence 47
São Paulo 44
Moscow 37
Helsinki 33
Hefei 32
Orem 32
Lachine 31
Dong Ket 26
Guangzhou 25
Lissone 25
Warsaw 25
Columbus 24
London 23
San Diego 23
Tokyo 23
Boardman 22
Boston 22
Da Nang 21
Haiphong 21
Denver 20
Shenyang 20
Montreal 19
Munich 19
Nanchang 19
Johannesburg 18
Ottawa 18
Phoenix 18
Brussels 17
Manchester 17
Pune 17
Tianjin 17
Baghdad 16
Fremont 16
Andover 15
Brooklyn 15
Changsha 15
Rio de Janeiro 15
Seoul 15
Atlanta 14
Chennai 14
Mexico City 14
Mumbai 14
Washington 14
Jakarta 13
Jiaxing 13
Bologna 12
Jinan 12
Poplar 12
San Francisco 12
Tashkent 12
Zhengzhou 12
Brasília 11
Dhaka 11
Nuremberg 11
Hebei 10
Istanbul 10
Jeddah 10
Kuala Lumpur 10
Nürnberg 10
Paris 10
Riyadh 10
Sacramento 10
Stockholm 10
Amman 9
Totale 9.317
Salva come PNG Salva come JPEG
Nome #
Impact of multidisciplinary team approach to liver tumors: 5-Years experience 528
Impact of multidisciplinary team approach to liver tumors in a tertiary center: 5-years experience 493
Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology 459
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 388
Value-based outcome indicators in the management of hepatocellular carcinoma: Clinical test in a large multicenter study (VBMH study) 364
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 345
Health related quality of life in chronic liver diseases 340
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 329
Trattamento con Sofosbuvir e Ribavirina nei pazienti hcv-positivi listati per il trapianto di fegato: un analisi di costo-efficacia 324
Generation and performance of value-based outcome indicators in liver disease: The multicenter V.B.M.H. study 323
Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naïve patients with Primary Biliary Cholangitis: a dual cut-off approach 322
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 318
Outcome indicators in liver cirrhosis: Application of value-based medicine in a large multicenter study (VBMH study) 316
Outcome Indicators in Primary Sclerosing Cholangitis: Interim Analysis Of The Value-Based Medicine In Hepatology (VBMH) Study 310
The impact of liver disease on the health-related quality of life 306
Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 305
P1169 : Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 304
A Comparison Between The Health-Related Quality Of Life Reported By The General Population And By Patients With Major Liver Diseases 292
Measurement of clinical outcomes and quality of life indicators as a new value-based approach to liver cirrhosis management 291
P0811 : Sofosbuvir-based direct-acting antivirals treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 290
Value-based outcome indicators in liver cirrhosis: validation in a large multicenter study (VBMH study) 289
Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis 289
Generation and Performance of Outcome Indicators in Liver Cirrhosis: The Value Based Medicine in Hepatology Study (V.B.M.H.) 287
Characteristics of patients with Chronic Hepatitis C who have failed past treatment or who have never been treated: How much room left for Interferon? 283
Impatto dei farmaci anti virali ad azione diretta sulla cura dei pazienti con epatite C: un approccio di value-based medicine 282
A value-based approach to the management of patients with liver cirrhosis through the systematic measurement of clinical outcome and quality of life indicators 275
Clinical treatment of cholangiocarcinoma: an updated comprehensive review 273
The Impact of Type of Liver Conditions on the Patients’ Health Related Quality of Life 273
Difference in health related quality of life of chronic liver diseases and general population 271
Health Related Quality of Life in the Major Liver Conditions 270
Value-based approach to hepatocellular carcinoma: outcome indicators tested in a large multicenter study (VBMH study) 269
Management of treatment-naïve chronic hepatitis C genotype 1 patients: A cost-effectiveness analysis of treatment options 264
Sofosbuvir-based all-oral treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 254
PGI31 Health Care Indicators to Measure Quality of Care in Patients with Liver Diseases 252
Should new antiviral treatments be considered in elderly Chronic Hepatitis C patients? 252
Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era 248
Should Sofosbuvir-Based All-Oral Treatment Be Considered In Elderly Chronic Hepatitis C Patients? 246
Applicazione della value-based medicine nella valutazione della cura dei pazienti affetti da epatite. 242
PGI36 Relationship Between Clinical Severity and Health Related Quality of Life in Chronic Liver Diseases 237
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 237
Impact of metformin on the incidence of human cholangiocarcinoma in diabetic patients: A systematic review and meta-analysis 227
The Cost-Effectiveness Of Sofosbuvir And Ribavirin Treatment In Hcv-Infected Patients Listed For Liver Transplantation 227
Management of chronic hepatitis C (Chc) genotype 1 treatment-naïve patients in an era of rising opportunities and costs: A cost-effectiveness analysis 223
Cost-effectiveness of Sofosbuvir plus Ledipasvir Antiviral Treatment for Elderly Patients with Chronic Hepatitis C Genotype 1 221
Functional liver imaging score (FLIS) can predict adverse events in HCC patients 221
Management of Chronic hepatitis C (CHC) Genotype 1 treatment-naive patients in an era of rising opportunities and costs - A cost-effectiveness analysis of treatment options 214
Hepatitis C virus infection and diabetes: a complex bidirectional relationship 201
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C 194
Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured? 192
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 187
Cost-effectiveness of new direct-acting antivirals to prevent post-liver transplant recurrent hepatitis 184
Sofosbuvir and ribavirinin in HCV-infected patients listed for liver transplantation: A cost-effectiveness analysis 178
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 157
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 139
Totale 15.005
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.360
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.360
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022771 70 87 87 85 32 57 13 53 37 65 49 136
2022/20231.344 144 446 121 111 82 170 31 82 97 9 38 13
2023/2024856 30 33 22 68 86 262 158 37 61 12 8 79
2024/20252.021 108 210 146 83 172 91 134 71 234 347 148 277
2025/20265.433 630 217 396 558 619 285 746 205 419 534 462 362
2026/202727 27 0 0 0 0 0 0 0 0 0 0 0
Totale 15.005